国内外外科手术围手术期抗凝治疗现状
|
摘要
静脉血栓栓塞症是外科手术患者常见的并发症,是患者围手术期死亡的主要原因之一。抗凝药物的使用在预防和治疗静脉血塞栓塞症中起到至关重要的作用。本文总结了外科手术患者围手术期血栓防治的国内外常用药物及特点,并对目前国内外围手术期抗凝管理指南进行综述。
Venous thromboembolism is a common complication of surgical patients and it is one of the main causes of death in perioperativepatients.The use of anticoagulants plays a vital role in the prevention and treatment of venous thromboembolism. This article reviews the commonly used drugs and the current guidelines for perioperative management of anticoagulation.
Venous thromboembolism is a common complication of surgical patients and it is one of the main causes of death in perioperativepatients.The use of anticoagulants plays a vital role in the prevention and treatment of venous thromboembolism. This article reviews the commonly used drugs and the current guidelines for perioperative management of anticoagulation.
引文
[1]中华医学会外科分会.中国普通外科围手术期血栓预防与管理指南[J].中华外科杂志,2016, 54(5):321-327.
[2]贾亮亮,柯永胜.急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗凝策略[J].中国临床药理学与治疗学,2013, 18(4):469-475.
[3] Caprini JA. Risk assessment as a guide to thrombosis prophylaxis[J].Current Opinion in Pulmonary Medicine, 2010, 16(5):448.
[4] BI E, OE D, MH H, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty(RE-NOVATEⅡ)[J]. Thrombosis&Haemostasis, 2011, 105(4):721-729.
[5] Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatranetexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:a randomised, double-blind, non-inferiority trial[J]. Journal of Thrombosis&Haemostasis, 2007, 5(11):2178.
[6] Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery[J]. British Journal of Surgery, 2005, 92(10):1212-1220.
[7] Turpie AG, Bauer KA, Caprini JA, et al. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery:a randomized, double-blind comparison[J]. Journal of Thrombosis&Haemostasis, 2007, 5(9):1854-1861.
[8]郁正亚.围手术期抗凝药物的使用[J].中华临床医师杂志:电子版,2011,05(16):4778-4783.
[9] Investigators E, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism[J]. New England Journal of Medicine, 2010, 363(26):2499.
[10]中华医学会心血管病学分会.华法林抗凝治疗的中国专家共识[J].中华内科杂志,2013, 52(1):76-82.
[11] Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141(2):326.
[12]静脉血栓栓塞症抗凝治疗微循环血栓防治共识专家组.静脉血栓栓塞症抗凝治疗微循环血栓防治专家共识[J].中华老年多器官疾病杂志,2017, 16(4):241-244.
[13] Keeling D, Tait RC, Watson H. Peri operative management of anticoagulation and antiplatelet therapy[J]. Br J Haematol, 2016, 175(4):602-613.
[14]中华医学会心血管病学分会,中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会.非瓣膜病心房颤动患者新型口服抗凝药的应用中国专家共识[J].中华心律失常学杂志,2014,(5):321-329.
[15]中华心血管病杂志编辑委员会血栓栓塞防治循证工作组.达比加群酯用干非瓣膜病心房颤动患者卒中预防的临床应用建议[J].中华心血管病杂志,2014,(3):188-192.
[16] Imberti D, Ambrosoli A, Cimminiello C, et al.Periprocedural management of rivaroxaban-treated patients[J]. Expert opinion on pharmacotherapy,2015, 16(5):685-691.
[17] Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery:cardiovascular assessment and managementThe Joint Task Force on non-cardiac surgery cardiovascular assessment and management of the European Society of Cardiology(ESC)and the European Society of Anaesthesiology(ESA)[J]. European Journal of Anaesthesiology(EJA), 2014, 31(10):517-573.
[18] Oscarsson A, Gupta A, Fredrikson M, et al. To continue or discontinue aspirin in the perioperative period:a randomized, controlled clinical trial[J].British journal of anaesthesia, 2010, 104(3):305-312.
[19] Mantz J, Samama CM, Tubach F, et al. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery:the multicentre, randomized, blinded, placebocontrolled, STRATAGEM trial[J]. British journal of anaesthesia, 2011,107(6):899-910.
[20] Devereaux PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery[J]. The New England journal of medicine,2014, 370(16):1494-1503.
[21] Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease:CHEST Guideline and Expert Panel Report[J]. Chest, 2016,149(2):315-352.
[22] Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology(ESC)[J]. European heart journal, 2016, 37(3):267-315.
[23]中华医学会外科学分会血管外科学组.深静脉血栓形成的诊断和治疗指南[J].中华普通外科杂志,2012,27(7):235-238.
[24] Heffner JE. Update of Antithrombotic Guidelines:Medical Professionalism and the Funnel of Knowledge[J]. Chest, 2016, 149(2):293.
[25] Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141(2 Suppl):419.
[2]贾亮亮,柯永胜.急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗凝策略[J].中国临床药理学与治疗学,2013, 18(4):469-475.
[3] Caprini JA. Risk assessment as a guide to thrombosis prophylaxis[J].Current Opinion in Pulmonary Medicine, 2010, 16(5):448.
[4] BI E, OE D, MH H, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty(RE-NOVATEⅡ)[J]. Thrombosis&Haemostasis, 2011, 105(4):721-729.
[5] Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatranetexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:a randomised, double-blind, non-inferiority trial[J]. Journal of Thrombosis&Haemostasis, 2007, 5(11):2178.
[6] Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery[J]. British Journal of Surgery, 2005, 92(10):1212-1220.
[7] Turpie AG, Bauer KA, Caprini JA, et al. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery:a randomized, double-blind comparison[J]. Journal of Thrombosis&Haemostasis, 2007, 5(9):1854-1861.
[8]郁正亚.围手术期抗凝药物的使用[J].中华临床医师杂志:电子版,2011,05(16):4778-4783.
[9] Investigators E, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism[J]. New England Journal of Medicine, 2010, 363(26):2499.
[10]中华医学会心血管病学分会.华法林抗凝治疗的中国专家共识[J].中华内科杂志,2013, 52(1):76-82.
[11] Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141(2):326.
[12]静脉血栓栓塞症抗凝治疗微循环血栓防治共识专家组.静脉血栓栓塞症抗凝治疗微循环血栓防治专家共识[J].中华老年多器官疾病杂志,2017, 16(4):241-244.
[13] Keeling D, Tait RC, Watson H. Peri operative management of anticoagulation and antiplatelet therapy[J]. Br J Haematol, 2016, 175(4):602-613.
[14]中华医学会心血管病学分会,中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会.非瓣膜病心房颤动患者新型口服抗凝药的应用中国专家共识[J].中华心律失常学杂志,2014,(5):321-329.
[15]中华心血管病杂志编辑委员会血栓栓塞防治循证工作组.达比加群酯用干非瓣膜病心房颤动患者卒中预防的临床应用建议[J].中华心血管病杂志,2014,(3):188-192.
[16] Imberti D, Ambrosoli A, Cimminiello C, et al.Periprocedural management of rivaroxaban-treated patients[J]. Expert opinion on pharmacotherapy,2015, 16(5):685-691.
[17] Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery:cardiovascular assessment and managementThe Joint Task Force on non-cardiac surgery cardiovascular assessment and management of the European Society of Cardiology(ESC)and the European Society of Anaesthesiology(ESA)[J]. European Journal of Anaesthesiology(EJA), 2014, 31(10):517-573.
[18] Oscarsson A, Gupta A, Fredrikson M, et al. To continue or discontinue aspirin in the perioperative period:a randomized, controlled clinical trial[J].British journal of anaesthesia, 2010, 104(3):305-312.
[19] Mantz J, Samama CM, Tubach F, et al. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery:the multicentre, randomized, blinded, placebocontrolled, STRATAGEM trial[J]. British journal of anaesthesia, 2011,107(6):899-910.
[20] Devereaux PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery[J]. The New England journal of medicine,2014, 370(16):1494-1503.
[21] Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease:CHEST Guideline and Expert Panel Report[J]. Chest, 2016,149(2):315-352.
[22] Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology(ESC)[J]. European heart journal, 2016, 37(3):267-315.
[23]中华医学会外科学分会血管外科学组.深静脉血栓形成的诊断和治疗指南[J].中华普通外科杂志,2012,27(7):235-238.
[24] Heffner JE. Update of Antithrombotic Guidelines:Medical Professionalism and the Funnel of Knowledge[J]. Chest, 2016, 149(2):293.
[25] Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141(2 Suppl):419.